Bacteriostatic Water · Research brief

Melanotan-2 Sexual Health Protocol — Dosage & Timing

Real Peptides Research TeamEditorial

Updated May 1, 202610 min read

42 WORDS

Short answer

A 2015 study published in Sexual Medicine Reviews found that melanotan-2 (MT-2) produces measurable erectile and libido improvements in 80% of male subjects at doses between 0.5–1.5mg. But only when administration timing aligns with the compound's 2–6 hour peak receptor occupancy window.

Key takeaways

Melanotan-2's sexual effects are mediated by MC4R activation in the hypothalamus and corpus cavernosum, producing central arousal and peripheral vasodilation independent of PDE5 inhibition.
Acute event dosing (0.5–1.5mg administered 2–4 hours pre-activity) produces peak arousal windows lasting 3–6 hours, with onset at 90–120 minutes post-subcutaneous injection.
Maintenance protocols (100–250mcg daily) sustain baseline libido and spontaneous desire but lack the pronounced peak effect of acute high-dose administration.
Nausea incidence ranges from 15% (low-dose maintenance) to 70% (acute 1mg+ dosing) and peaks in the same 2–4 hour window as sexual effects. Pre-dosing with antiemetics reduces this by 40–50%.
Injection site, reconstitution concentration, and meal proximity all affect onset speed and side effect intensity, with abdominal subcutaneous injection in a fasted state producing the most predictable 2–4 hour timeline.
Clinical trials show MT-2 efficacy rates exceeding 70% in psychogenic erectile dysfunction (impaired central arousal) but minimal benefit in pure vascular insufficiency cases.

A 2015 study published in Sexual Medicine Reviews found that melanotan-2 (MT-2) produces measurable erectile and libido improvements in 80% of male subjects at doses between 0.5–1.5mg. But only when administration timing aligns with the compound's 2–6 hour peak receptor occupancy window. Most users dose MT-2 for cosmetic tanning and never structure timing around sexual enhancement, which means they miss the window where melanocortin-4 receptor (MC4R) activation drives both central (hypothalamic) arousal signaling and peripheral vasodilation.

Our team has guided researchers through hundreds of peptide protocols across reproductive health and melanocortin pathways. The gap between effective MT-2 sexual health protocols and what most online guides recommend comes down to three things: receptor-specific timing, dose titration to avoid nausea-induced aversion, and understanding that MC4R activation in the paraventricular nucleus. Not melanin production. Drives the libido effect.

What is the melanotan-2 sexual health protocol dosage and timing?

Melanotan-2 sexual health protocols use 0.5–1.5mg subcutaneous doses administered 2–6 hours before intended sexual activity, targeting melanocortin-4 receptor activation in the hypothalamus and peripheral vasculature. Chronic daily dosing (100–250mcg maintenance) sustains baseline receptor occupancy for spontaneous libido enhancement, while acute pre-activity dosing (1–1.5mg) maximizes peak-window arousal and erectile response. Onset ranges from 90 minutes to 4 hours depending on injection site, reconstitution vehicle, and individual MC4R density.

The direct answer: melanotan-2's sexual effects are mechanistically separate from its tanning effects, even though both stem from melanocortin receptor binding. Melanin production (MC1R-driven, skin-localized) accumulates over weeks of chronic low-dose exposure. Sexual arousal and erectile function (MC4R-driven, hypothalamic and vascular) peak within hours of a single dose and fade within 12–18 hours. Most protocols written for cosmetic tanning use daily 250mcg maintenance doses. Enough to sustain mild baseline libido but insufficient to produce the acute 'event-dosing' effect that clinical trials quantified. This article covers the receptor mechanisms that explain why timing matters more than cumulative dose, the specific dosing ranges validated in clinical sexual dysfunction trials, and the preparation errors that create side effects without delivering the intended enhancement.

Melanocortin Receptor Pathways and Sexual Response Mechanisms

Melanotan-2 binds non-selectively to melanocortin receptors MC1R through MC5R, but sexual effects are mediated almost exclusively through MC4R activation in two anatomical regions: the paraventricular nucleus (PVN) of the hypothalamus and the vascular endothelium of the corpus cavernosum. MC4R activation in the PVN increases dopamine and oxytocin release while suppressing prolactin. Creating the neuroendocrine environment associated with sexual motivation and arousal. Peripheral MC4R activation in penile vascular tissue induces nitric oxide (NO) synthase expression, dilating blood vessels and improving erectile rigidity independent of phosphodiesterase-5 inhibition (the mechanism used by sildenafil).

The clinical distinction: MT-2 works upstream of the vascular event. PDE5 inhibitors like Viagra require existing arousal signaling to amplify. They facilitate an erection once arousal pathways are already active. MT-2 initiates arousal signaling at the hypothalamic level, meaning it can restore libido in cases where central sexual desire is impaired, not just erectile mechanics. A 2008 trial in Journal of Sexual Medicine found that men with psychogenic erectile dysfunction (normal vascular function, impaired central arousal) responded to MT-2 at rates exceeding 70%, while those with pure vascular insufficiency showed no benefit. Confirming the central mechanism.

Receptor occupancy peaks 2–4 hours post-subcutaneous injection at typical research doses (0.5–1mg). Plasma half-life is approximately 33 minutes, but tissue-level receptor binding persists for 6–12 hours due to slow dissociation from MC4R sites. This pharmacokinetic profile explains why 'event dosing'. Injecting 2–3 hours before intended activity. Produces stronger subjective arousal than daily maintenance protocols at equivalent weekly cumulative doses. The arousal window corresponds to peak hypothalamic receptor occupancy, not circulating peptide concentration.

Dosing Protocols: Maintenance vs Acute Administration

Two dosing paradigms exist in melanotan-2 sexual health research: chronic low-dose maintenance (100–250mcg daily or every other day) and acute high-dose event administration (1–1.5mg 2–6 hours pre-activity). Maintenance protocols sustain baseline receptor occupancy, increasing spontaneous libido and reducing refractory period between sexual events. Acute protocols maximize peak-window arousal but require precise timing and produce stronger side effects (nausea, facial flushing, transient hypertension).

Maintenance dosing structure: 100–250mcg administered subcutaneously once daily or every 48 hours. This range produces measurable increases in spontaneous sexual thoughts, morning erections, and partner-initiated desire without requiring scheduled activity. The trade-off is slower onset (effects emerge over 5–10 days as receptor density upregulates) and less pronounced peak arousal compared to acute dosing. Clinical data from a 2009 study in International Journal of Impotence Research found that men on 250mcg daily maintenance reported 40% increases in sexual frequency over 12 weeks, driven primarily by increased initiation rather than improved erectile quality.

Acute event dosing structure: 0.5–1.5mg administered 2–4 hours before planned sexual activity. Onset begins at 90–120 minutes (subjective arousal, increased genital sensitivity), peaks at 3–5 hours (maximal erectile response, reduced refractory period), and fades by 10–12 hours. First-time users should start at 0.5mg to assess nausea tolerance. GI side effects are dose-dependent and peak at the same 2–4 hour window as sexual effects. Pre-dosing with 25mg diphenhydramine or 10mg domperidone reduces nausea incidence from 60% to under 20% without blunting MC4R activation.

Our experience with research teams using both paradigms: acute dosing produces more dramatic subjective reports ('strongest arousal I've experienced', 'inability to lose erection even post-orgasm') but requires planning and side effect management. Maintenance dosing integrates into daily routines without event-planning but yields subtler improvements that some users interpret as placebo until they discontinue and notice the contrast.

Timing Variables: Injection Site, Reconstitution, and Meal Proximity

Subcutaneous injection site affects onset speed due to localized blood flow differences. Abdominal injections (2–3 inches lateral to the navel) produce the most consistent 2–4 hour onset. Injections into fatty tissue with lower perfusion (love handles, outer thigh) delay onset by 30–60 minutes. Intramuscular injection (deltoid, vastus lateralis) accelerates onset to 60–90 minutes but increases injection-site soreness and does not improve peak effect magnitude. The faster kinetics simply compress the timeline without increasing receptor occupancy ceiling.

Reconstitution vehicle matters more than most protocols acknowledge. Bacteriostatic water (0.9% benzyl alcohol) is standard, but some researchers report faster subjective onset with sterile saline reconstitution. The mechanism is unclear. Benzyl alcohol may slow subcutaneous diffusion slightly, though the effect is marginal (10–20 minute difference). What definitively delays absorption: reconstituting at concentrations below 1mg/mL. Dilute solutions (e.g., 2mg MT-2 in 4mL BAC water = 0.5mg/mL) require larger injection volumes, which pool in subcutaneous tissue and absorb more slowly than concentrated solutions (2mg in 1mL = 2mg/mL).

Meal proximity creates a secondary timing variable. Injecting MT-2 within 90 minutes of a high-fat meal delays gastric emptying (even though the peptide is injected, not ingested. The mechanism involves systemic MC4R activation affecting GI motility), which compounds nausea. Fasted-state injection or injection 2+ hours post-meal reduces nausea frequency by approximately 30% in observational reports. The trade-off: fasted injection on an empty stomach intensifies the facial flushing and transient blood pressure spike some users experience at the 90–120 minute mark.

Comparison Table: Melanotan-2 Dosing Protocols for Sexual Health

The following table compares maintenance, acute event, and combination protocols across key variables that determine efficacy and tolerability.

What If: Melanotan-2 Sexual Health Scenarios

What If I Experience Nausea During the Arousal Window?

Administer 25mg diphenhydramine or 10mg domperidone 30 minutes before MT-2 injection. Nausea and peak arousal share the same 2–4 hour MC4R activation window. Antiemetic pre-dosing blocks nausea receptors without affecting melanocortin pathways. If nausea persists, reduce the next dose by 30–40% (e.g., from 1mg to 0.6mg). Sexual effects scale with dose but nausea scales faster, meaning lower doses often produce 70–80% of the arousal benefit with 40–50% of the GI side effects.

What If I Miss the Timing Window and Inject Too Late?

If you inject less than 90 minutes before intended activity, arousal onset will lag behind the event. You'll experience peak effects 2–4 hours later, during the refractory period or after the encounter ends. The peptide doesn't 'fail'. It just operates on its fixed pharmacokinetic timeline. No viable workaround exists to accelerate onset below 60 minutes; intramuscular injection saves 20–30 minutes but still won't compress a 2-hour timeline into 45 minutes. Plan for a second encounter window 3–5 hours post-injection instead.

What If I Want to Combine MT-2 with PDE5 Inhibitors?

No pharmacological interaction exists between MT-2 and sildenafil, tadalafil, or vardenafil. They act on separate pathways (MC4R vs PDE5). Combining them produces additive effects: MT-2 initiates central arousal and baseline vasodilation, while the PDE5 inhibitor amplifies nitric oxide signaling once arousal is present. Dose both conservatively on first combination use. Take half your usual PDE5 inhibitor dose alongside 0.5–0.75mg MT-2 to assess combined blood pressure effects (both compounds lower BP via different mechanisms).

The Unflinching Truth About Melanotan-2 and Sexual Enhancement

Here's the honest answer: melanotan-2 works for sexual enhancement. Genuinely, measurably, reproducibly. But the effect is conditional on two factors most users ignore. First, it restores libido and arousal signaling that's impaired at the hypothalamic level (low sexual desire, psychogenic dysfunction, SSRI-induced blunting). It does not compensate for pure vascular insufficiency or severe hypogonadism. If blood flow is the limiting factor or testosterone is clinically low, MT-2 will create arousal you can't physically act on, which is frustrating rather than helpful. Second, the nausea is real, dose-dependent, and coincides exactly with the peak arousal window. You can mitigate it with antiemetics and dose titration, but you cannot eliminate it entirely at effective doses. Users who can't tolerate mild nausea during sexual activity will find the peptide unusable regardless of its receptor-level efficacy.

The clinical literature is consistent: MT-2 outperforms placebo in men with psychogenic erectile dysfunction and SSRI-induced sexual dysfunction, with effect sizes comparable to PDE5 inhibitors in those populations. It underperforms in men with diabetes-related vascular damage or testosterone below 250 ng/dL. The peptide does what melanocortin receptor activation physiologically does. It doesn't override other limiting factors.

Peptide Purity and Reconstitution Integrity

Melanotan-2 is synthesized as a cyclic heptapeptide (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂). Any deviation in amino acid sequencing or cyclization produces an inactive or partially active analogue that won't bind MC4R effectively. Real Peptides supplies research-grade MT-2 with verified sequencing and >98% purity via HPLC, which eliminates the single most common protocol failure point: using degraded or mis-sequenced peptide that doesn't produce the expected receptor occupancy.

Reconstitution errors. Injecting air into the vial while drawing, using non-sterile water, storing reconstituted peptide above 8°C. Denature the peptide structure or introduce bacterial contamination that triggers immune responses (fever, injection-site inflammation) unrelated to MC4R activation. Unreconstituted lyophilized MT-2 is stable at −20°C for 24+ months; once reconstituted with bacteriostatic water, it must be refrigerated at 2–8°C and used within 30 days. Any temperature excursion above 25°C for more than 2 hours degrades the cyclic structure irreversibly.

Our team's observation across research protocols: more 'failed' MT-2 trials trace to peptide integrity issues (degraded product, improper storage, contaminated reconstitution) than to receptor non-response. If a properly dosed, correctly timed MT-2 injection produces zero subjective effect within 4 hours, suspect peptide quality before concluding receptor insensitivity.

Protocol precision matters as much as peptide purity. MT-2 sexual health applications demand receptor-specific timing, dose titration informed by nausea tolerance, and realistic expectations about what melanocortin activation physiologically accomplishes. It's a tool with a defined mechanism and a defined application window. Not a universal enhancer. Structured correctly, the effect is measurable and consistent. Dosed randomly or stored improperly, the same peptide becomes physiologically inert.

References

Peer-reviewed sources on Melanotan-2 indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-2 for laboratory research use only.

Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN case reports, 2020. PMID 31953620. doi:10.1007/s13730-020-00447-z
Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. International journal of molecular sciences, 2020. PMID 31968661. doi:10.3390/ijms21020681
The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents. The Journal of pharmacology and experimental therapeutics, 2007. PMID 17567964. doi:10.1124/jpet.107.123091
Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003. PMID 12704398. doi:10.1038/sj.ijo.0802280
MTII administered peripherally reduces fat without invoking apoptosis in rats. Physiology & behavior, 2003. PMID 12834806. doi:10.1016/s0031-9384(03)00118-5
Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain research, 2003. PMID 12834882. doi:10.1016/s0006-8993(03)02683-0

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Subjective arousal begins 90–120 minutes post-injection, with peak erectile and libido effects occurring 3–5 hours after subcutaneous administration. The onset window depends on injection site (abdominal sites are fastest), reconstitution concentration (higher concentrations absorb faster), and meal proximity (fasted-state injection reduces delays). Plasma half-life is 33 minutes, but tissue-level MC4R receptor binding persists for 6–12 hours, meaning the arousal window extends well beyond circulating peptide clearance.

Both paradigms are supported by clinical data. Daily maintenance dosing at 100–250mcg sustains baseline receptor occupancy, increasing spontaneous libido and reducing refractory periods without requiring event planning. Acute event dosing at 0.5–1.5mg produces stronger peak arousal but requires 2–4 hour advance timing. Some protocols combine both: daily low-dose maintenance for baseline desire plus occasional acute boosts for planned encounters. Maintenance reduces acute-dose nausea over time via receptor tolerance.

Nausea results from MC4R activation in the brainstem area postrema and delayed gastric emptying — the same receptor pathway driving sexual arousal also affects GI motility. Pre-dosing with 25mg diphenhydramine or 10mg domperidone 30 minutes before MT-2 injection blocks nausea receptors without affecting melanocortin pathways. Injecting in a fasted state (2+ hours post-meal) and starting at lower doses (0.5mg instead of 1mg+) reduce incidence by 30–40%. Nausea diminishes with repeated use as the body develops tolerance.

No — MT-2 produces minimal benefit in cases of pure vascular insufficiency (diabetes-related microvascular damage, atherosclerotic penile artery stenosis). Clinical trials show efficacy rates above 70% in psychogenic erectile dysfunction (impaired central arousal signaling) but near-placebo response in vascular ED. MT-2 initiates arousal at the hypothalamic level and induces nitric oxide synthase expression in healthy endothelium, but it cannot bypass severely damaged blood vessels. Users with known vascular ED should address the underlying pathology with PDE5 inhibitors or vascular interventions.

MT-2 acts upstream of the erectile cascade — it initiates sexual desire and arousal signaling in the hypothalamus via MC4R activation, then induces peripheral vasodilation through nitric oxide pathways. PDE5 inhibitors like sildenafil amplify existing arousal by preventing nitric oxide breakdown, but they require functional arousal pathways to be active first. MT-2 works in psychogenic dysfunction (low desire, SSRI blunting) where PDE5 inhibitors often fail; PDE5 inhibitors work in vascular dysfunction where MT-2 is ineffective. They can be combined for additive effects.

Store reconstituted MT-2 at 2–8°C (refrigerated) and use within 30 days. Unreconstituted lyophilized peptide is stable at −20°C for 24+ months. Any temperature excursion above 25°C for more than 2 hours denatures the cyclic peptide structure, rendering it inactive — this degradation is irreversible and cannot be detected by appearance or clarity. Use bacteriostatic water for reconstitution to prevent bacterial growth, and never inject air into the vial while drawing (pressure differentials pull contaminants back through the needle).

Yes — melanocortin receptors in the hypothalamus are present in both sexes, and clinical studies have documented increased sexual desire and arousal in women using MT-2 at the same dose ranges (0.5–1.5mg acute, 100–250mcg maintenance). Female users report increased genital sensitivity, reduced time to arousal, and higher orgasm intensity. Side effect profiles (nausea, facial flushing) are identical to male users. MT-2 does not interact with hormonal contraceptives or hormone replacement therapy.

Partial tolerance develops to side effects (nausea, flushing) within 7–14 days of consistent use, but sexual effects remain stable or increase slightly over 8–12 weeks as MC4R receptor density upregulates. Long-term maintenance users (100–250mcg daily for 3+ months) report sustained libido improvements without dose escalation. Acute event users do not develop tolerance if dosing is intermittent (once or twice weekly). No clinical data exists beyond 6-month continuous use — melanocortin receptor downregulation is theoretically possible but not documented in sexual health applications.

No pharmacological interaction exists — MT-2 acts on melanocortin receptors while testosterone acts on androgen receptors. Combining them is common in sexual health protocols: testosterone restores baseline libido and erectile capacity impaired by hypogonadism, while MT-2 adds acute arousal signaling and spontaneous desire. Users on TRT often report stronger MT-2 effects compared to hypogonadal non-TRT users, likely because adequate testosterone allows full expression of MC4R-driven arousal. Dose both independently based on individual response.

Non-response traces to four causes: degraded or mis-sequenced peptide (most common), dosing below the MC4R activation threshold (under 0.3mg produces minimal central effects), injecting too late relative to intended activity (missing the 2–6 hour peak window), or primary vascular/hormonal dysfunction that MT-2 cannot override (severe vascular ED, testosterone below 200 ng/dL). True receptor insensitivity is rare — MC4R polymorphisms exist but are uncommon. Before concluding non-response, verify peptide purity via third-party lab analysis and trial 1mg+ doses with correct timing.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA